Compass Therapeutics Inc. (CMPX)
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CMPX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $123.94M
- EPS (TTM)
- -$0.46
- Dividend yield
- None
- 52-week range
- 0.57 – 6.88
- Day range
- 0.6405 – 0.7297
- Volume / Avg
- 1.82M / 3.88M
- Beta
- —
- Shares outstanding
- 180.09M
52-week range
CMPX stock today
Compass Therapeutics (CMPX) closed at $0.6882 on Nov 20, up 1.43% (+$0.0097), versus the S&P 500's 3.70% decline. Trading was light, with 1.82M shares changing hands, about 47% of the average daily volume. At this level, CMPX sits near the bottom of its 52-week range of $0.57 to $6.88: 90.0% below the high, set on Feb 3, 2026 and 20.7% above the low.
CMPX is down 87.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.9%. Compass Therapeutics has posted a net loss over the last twelve months (EPS of -$0.46), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Compass Therapeutics
Company profileCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Thomas J. Schuetz M.D., Ph.D.
- Headquarters
- Boston, MA
- Employees
- 39
- Website
- compasstherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Compass Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 9 years shown. Compass Therapeutics reported a net loss of $66.5 million, compared with a loss of $49.4 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $850.00K | $0 | — | — |
| Growth | -100.00% | — | — | — | — |
| Net income | $-66.49M | $-49.38M | $-42.49M | $-39.23M | $-82.18M |
| EPS (diluted) | — | — | — | — | $-1.31 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$5.26+664.31%
- Strong buy 2
- Buy 10
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.15 vs $-0.12
- Surprise
- -25.00%
CMPX news
All CMPX news- Compass Therapeutics, Inc. Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNasdaq
- Compass Therapeutics, Inc. Reports 2026 Third Quarter Financial Results and Net loss of $27.2 millionNasdaq
- Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswire
- Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual MeetingGlobeNewswire
- Compass Therapeutics to Participate in Upcoming November Investor EventsGlobeNewswire
- Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026GlobeNewswire
- Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Compass Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs CMPX |
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs CMPX |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs CMPX |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs CMPX |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs CMPX |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs CMPX |
| TARAProtara Therapeutics Inc. | 2.28 | -5.00% | $140.38M | vs CMPX |
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs CMPX |
Indexes, lists and sector
Compass Therapeutics stock FAQ
What is Compass Therapeutics's stock price today?
CMPX last traded at $0.6882 as of Nov 20, 4:00 PM EST, up 1.43% on the day. Prices are delayed at least 15 minutes.
Who is Compass Therapeutics's CEO?
Dr. Thomas J. Schuetz M.D., Ph.D. is the chief executive officer of Compass Therapeutics Inc., which has about 39 employees.
What is the CMPX 52-week high?
The 52-week high for CMPX is $6.88 and the 52-week low is $0.57. The stock is currently 90.0% below its high.